Performant Financial Corporation Q1 2023 Earnings Call
Okay.
[music].
Good afternoon, ladies and gentlemen, and welcome to the pro forma financial first quarter 2023 earnings Conference call.
At this time all lines are in a listen only mode.
During the presentation, we will conduct a question and answer session.
If at any time during this call you require immediate assistance. Please press star zero for the operator.
This call is being recorded on Tuesday may nine 2023.
I would now like to turn the conference over to Richard Vivek, Vice President Investor Relations. Thank you Richard.
You may begin.
Operator, good afternoon, everyone by now you should have received a copy of the earnings release for the company's first quarter 2023 results. If you have not a copy is available on the Investor relations portion of our website.
On today's call will be Lisa M Board chair.
Simeon co Chief Executive Officer, and Rohit, Rhumbatron, Donnie Chief Financial Officer.
Before we begin I would like to remind you that some of the comments made on today's call, including our financial guidance are forward looking statements. These statements are subject to risks and uncertainties, including those described in the company's filings with the SEC.
Our actual results may differ materially from those described during the call in.
In addition, all forward looking statements are made as of today and the company does not undertake to update any forward looking statements based on new circumstances or revised expectations.
All non-GAAP financial measures disclosed during this call are reconciled to the most directly comparable GAAP measures in the table attached to our press release.
I'd like to formally announce that the company will be hosting its inaugural Investor day event on June 20th in New York City. Please contact me via E. Mail, if you would like additional information or have interest in attending.
I would now like to turn the call over to Lisa.
Lisa.
Thank you rich good afternoon, everyone and thank you for joining us for our earnings call. We are announcing several changes today, which make the future of performance even more exciting.
I'm proud of the effort that the entire team gives each and every day as it has allowed us to pursue and grow our healthcare business in ways that many thought impossible.
You all for your dedication and hard work.
As you already read in our press release, I am stepping down as CEO of procurement.
To finance and strategy for the past two years.
In that role Rohit successfully navigated the actions to transform performance away from its legacy recovery business and continue investing into the health care market.
With that we want to congratulate both Simeon and Rohit on their promotions.
I turn the call over to our new CEO Jim.
Thanks, Lisa and good afternoon, everyone I am truly honored for the opportunity to lead this amazing organization of dedicated and talented professionals.
With our clarity of vision, and our relentless commitment to delivering value to our clients I.
I am confident that we can achieve our goals and take performance to new Heights.
From the time I joined performance in 2012 through our FERC quarter of 2023, I have been fully invested in our long term success.
As I previously shared our ability to expand services with an existing clients remains a key pillar of our success.
And our sales pipeline of new opportunities continues to grow as a result of our increased focus.
Mid market payers.
However, key to achieving our growth objectives.
The timely conversion of these new opportunities into revenue producing engagement.
During the first quarter of 2023.
Definitely delivered on this objective.
By completing 11, new commercial implementation and.
And for context, the 11, new implementations during the quarter as more than half as many as we did in all of 2022, which was an impressive year of new implementations in its own right.
As impressive as our implementation cadence was in the first quarter there is still room for improvement.
We're making investments into our platforms and workflows and we expect these investments coupled with the demonstrated commitment of our team.
Yield dividends during this year and into 2024.
With regards to the public health emergency we are encouraged that president Biden ended the national emergency last month, and we expect the public health Emergency will officially end later this week.
Showing the end of the PHP. It is expected that the health care industry could face a number of administrative challenges our clients. However indicate that these challenges could be minimal and temporary we.
We will continue to be a strong partner to our clients. During this transition period and hopefully the final step toward a return to normal fee from the era of COVID-19.
Our revenues in the FERC quarter of 2023 were lower compared to the first quarter of 2022, due primarily to a decline in demand inventory within our Dms MSP business.
Beyond what we could have anticipated.
Demand volume under this contract is driven by industry wide set from 111 reporting.
This reporting can ebb and flow according to a myriad of factors many of which are beyond our control.
It is worth noting however that the demand volumes have already returned to expected levels and we anticipate that there is a potential to recoup roughly $5 million of revenue over the remainder of the current year associated with the Q1 dip.
Our audit our claims based business continued to achieve double digit year over year revenue growth.
A trend we anticipate continuing at previously implemented contracts mature combined with the ramping of new programs and our current expectations for future implementation.
We are also seeing early results on our initiatives to increase scale and drive greater efficiency within the claims based business and.
And speaking of implementations and future revenue growth. We are happy to report that during Q2, we completed certain implementation activities for our new rack region too.
Our teams have made amazing progress in tandem with CMS is dedicated effort and we anticipate the commencement of some operations this quarter we.
We believe that BD implementation marked a milestone for the CMS rap program demonstrating that performance has the knowledge and capability to facilitate the transition of any rack region or other similarly large audit program.
Within the eligibility business, we continued to make progress with our commercial growth initiatives.
In particular the implementations we completed during Q4 of last year and Q1 of 2023 will be key in supporting our growth expectations for the remainder of 2023 and beyond.
Within our government eligibility work the renewed CMS MSP contract is now fully operational and as I mentioned the available inventory of demand is trending back to the norm.
So the first quarter was weighed down by a dip in the available MSP inventory, we remain bullish on 2023.
Our sales pipeline is robust and our cadence of new program implementation is progressing at.
Or quite frankly at times greater than expected.
Both our eligibility and claims based businesses are exceeding milestones in the rollout of new mid market opportunities.
As well as the expansion of existing national programs and our initiatives to improve scale are showing strong promise.
Before I hand, the call over to Rohit to go over the results from the quarter I wanted to take a moment to congratulate him on his promotion to CFO .
<unk> has served as a trusted partner during our years of healthcare growth and company transformation.
Excited to continue our partnership as we progress into the next chapter of performance Health care solutions.
With that I'll hand, it over to Rohit, our chief financial Officer for a discussion of the financials Rohit.
Thanks, Tim I'm really excited to continue serving the company and our many constituents as performance CFO .
Its remarkable to have been a part of the journey, thus far and have an inside view to all the strategic and financial momentum, we have made and I'm eager to continue contributing toward our ongoing progress.
With that let's dive into the quarter's results are.
Our first quarter 2023 results reflect our continued efforts to grow our healthcare market operation and we remain pleased and excited with our trajectory.
Total company revenues in the quarter were $25 7 million, which included healthcare revenues of $22 nine.
Our customer care outsourced services business accounted for $2 $8 million during the quarter a decline from last quarter, but in line with our expectations for this business as we continue to anticipate shrinking customer care market revenues sort of the restart process of federal student loan programs.
As Tim noted our healthcare revenues in the first quarter had a downward trend primarily driven by our eligibility government programs, specifically, our CNS MSP work.
But we continue to see strong performance within our commercial clients are key growth channel.
As a result of the government volume declines revenues from our eligibility services for the first quarter of 2023 were $12 5 million or a decrease of just over 12% when compared to the roughly $14 million reported in the first quarter of 2022.
As Tim mentioned, we've seen the volumes return and anticipates a potential to recoup a portion of the missed revenues across the remainder of the current year I'd.
I'd also like to note that the rest of our eligibility programs are currently displaying growth consistent with the efforts of historical implementations.
Overall, we expect the 2023 annual revenues from eligibility services to meet and likely exceed dose of 2022.
Within our claims base business also known as claims auditing our revenues in the first quarter were 2000 22023 were roughly $10 4 million, which was an increase of nearly 14% compared to the $9 1 million in the first quarter of 2022, we anticipate this growth trend to continue.
Moving on to expenses.
Operating expenses in the first quarter were $29 5 million, which equates to approximately $1 million higher compared to the first quarter of last year.
This was primarily driven by increases in head count salaries, and partially offset by lower other operating expenses.
We currently anticipate at the increases in salaries and head count will continue to drive growth in operating expenses in the upcoming quarters. As we continue with the implementation and are pleased that we are not experiencing the hiring headwinds we experienced early last year.
As Tim mentioned, we're excited about our current implementation cadence and the potential for margin expansion as a result of our various investment activities I would like to reaffirm our guidance for 2023 health care revenues to be in the range of $105 million to $110 million and for the full year 2023, adjusted EBITDA to be in the range of 2%.
$5 million, which is reflective of our ongoing investment in growth initiatives as well as improvements in our operational efficiencies.
We are excited to continue growing the business and have our eye on both our revenue targets and the expansion of EBITDA margins.
Aside from operational improvements as we continue to scale, we anticipate seeing a natural expansion of our margins through operating leverage. This is supported by management's estimated gross margins of the blend of our various markets around 40 as it stands today with room for expansion.
We are encouraged by what we're seeing thus far in 2023, our long term strategy remains steady and we are excited to continue delivering results as we march toward a larger and stronger future.
Operator will you. Please open up the line for questions.
Thank you ladies and gentlemen, you will now begin the question and answer session.
Do you have a question. Please press star followed by the number one on your Touchstone signing.
And then if you have a question. Please press star followed by the number one on your Touchtone sign.
I would like to withdraw your request. Please press star followed by the number please.
Please standby, while we compile the Q&A laskin.
Your first question comes from the line of George Sutton.
From Craig Hallum. Please go ahead.
Hey, Simeon.
Rohit. This is James on for George Congratulations on the promotions.
So first off the 11 commercial implementations really stood out.
Thank you your expectations, where basically for similar cadence as you saw last year, which means about five a quarter.
So what sort of drove the strength there can you talk about the mix between audit and eligibility and then could.
Could you talk about sort of the cadence that you expect throughout the remainder of the year.
Yes.
Okay. Thank you and I think I can hit your latter question and then Tim if you want to comment on sort of the driving of the 11 minutes.
But in terms of them.
The split is actually pretty healthy between audit and eligibility and were pleased to see this because I think as we've shared in the past year, we had a little more skewing towards claims auditing implementations.
Into our pipeline across 22, so happy to see that return to more of a healthy split.
And this year and I think we.
We do anticipate that.
This strong cadence.
Similar to last year or better as <unk> seen should continue.
Yeah, and James coming in here so.
So look I think it's also a reflection of what we've been talking about in terms of.
A healthy sales pipeline and the efforts the team has in terms of converting those sales too.
Signing deals.
So we look at some of the opportunities and we have a focus right now and trying to push them through the pipeline as quickly as we can to get them to contracted opportunities and then once they're contracted and it really is around what we've discussed and we've heard in the prepared remarks around how we have an internal initiative to really try to move from contracting to revenue.
And so in doing that we have a focus around just trying to expedite the timeframe of getting data in house getting audits or eligibility depending on the service ramped up and so that ultimately seeing a larger number there is just a pure reflection of we've made some progress in X.
<unk> that kind of onboard process.
Great.
And then some of the larger payers and CMS has sort of made moves to reduce preauthorizations.
I would assume that would be a positive for your business, particularly on the audit side and I'm just kind of curious if that's come up in conversation.
Yes, it's a good call out right. So I think historically, depending on policy of the various payer.
That's pre off is something that we typically can look at from an audit perspective, as you might imagine and so again, it depends payer to payer and various policies, but certainly removing that pre authorization does give us more opportunity to look at claims that would otherwise be designated as a new.
Overview.
Great.
Last one for me are you able to sort of speak to any success that you've seen so far through your relationship with CA Q H and I will hop back.
Yeah no. We appreciate it we are both on in terms of opportunities.
As we anticipated.
I think the payer community is recognizing the value that both organizations <unk> performance, bringing together in terms of leveraging their asset their data asset through the capabilities and skills that we have.
So we're seeing increased opportunities in the pipeline as we anticipated.
And though still a little bit in the early innings here.
But we are meeting or exceeding expectations in terms of just some of the operational components.
With with a few clients that we have underway.
Thank you. Your next question comes from the line of Jacob Stefan from Lake Street Capital markets. Please go ahead.
Hey, guys like to extend my congratulations as well.
I guess first just focusing in here.
Could you talk about the commercial.
Commercial payer revenue I know last quarter, you guys and broken it out.
66%.
Just wondering if you could update us on.
Revenue from commercial payers.
Hey, Jacob.
And yes, so last last quarter, we had broken it out on an annual basis, and we will endeavor to do so again this year I think particularly with the way we guide to an annual number and the cadence between quarters, we believe that.
It's more meaningful to dig into on an annual basis.
We'll continue to evaluate it.
It ends up.
Becoming a different view.
For now what I can share is I think the commercial programs are still showing a very strong growth rate double digits and should drive the expectations. We shared last quarter sort of a lot of our current year growth continuing to stem from the commercial side.
Okay.
That's helpful.
Maybe just focusing on the.
The public health emergency ending here.
Have you guys heard any more kind of.
Any way to quantify maybe how many claims may become available.
How those may I.
I guess bleed out over.
The coming years.
Yeah. So.
Thanks for the question specifically the answer is no we have not been able to.
To quantify that and I think in context, we're talking two components one is.
Historical look back right. So is there any tailwind associated with claims that we're untouchable, because there was a COVID-19 diagnosis and.
Once the phe expires do some of those claims get move back into the system as long as statue limitations have an expired et cetera and so.
So we've been working with the CMS and the various payers to just try to understand what the appetite for those claims are and what the policies are going to be.
We're looking forward to trying to get greater clarity around that and once this phe at the end of this week is finally expired.
But we don't have any real good indication to share with you what that might look like in terms of upside.
I can tell you, though that it's beyond just the historical claims that have been quote unquote turned off because of because of COVID-19 in terms of our access to them, but there is also claims that would.
Would otherwise be in our system that were also kind of put to the sideline because they had some correlation with COVID-19. So if you think about our concepts and what we ultimately look at they could have things such as oxygen and <unk> durable medical equipment that are tied to a COVID-19 diagnosis and we had many.
Of our payers also restrict some of those particular concepts, which impacted inventory. So it's a two prong we are going to start learning more.
Certainly more bullish on the fact that we will see those concepts turn on.
Quicker, then we will get access or an understanding of what possibility or for historical inventory, but look overall as we've been saying, having this behind us as only a helpful component of our business, but I think it's important to point out that these things don't happen overnight and we're just going have to work through.
With the payer communities to understand how they're going to kind of apply policies and then what the impact and timing is for our business.
Okay. That's helpful.
That does it for me best of luck going forward guys.
We appreciate it.
Thank you there are no further questions at this time I'd now like to turn the call back over to management for any closing remarks.
We thank you for joining us today and we appreciate all the support of our investors I. Appreciate all the hard efforts of the performing team members and we look forward to rejoining you on next quarters conference call. Thank you.
Thank you Sir thank you so much presenters ladies and gentlemen. This concludes your conference call for today, we thank you for participating and ask that you. Please disconnect your lines have a lovely day.